MSD Buys Wuxi’s Irish Vaccines Plant for €500 Million
MSD Expands Vaccine Production in Ireland with €500 Million Dundalk Acquisition
Dundalk, Ireland – Pharmaceutical giant MSD is bolstering its vaccine production capabilities in Ireland with the acquisition of a state-of-the-art vaccines plant in Dundalk for €500 million. The facility, previously owned by Chinese rival Wuxi Biologics, will add 150 jobs to the local economy and further solidify MSD’s presence in the country.
The Dundalk plant, which began operations in 2019, has been exclusively manufacturing vaccines for MSD under a 20-year supply contract.The transition to full MSD ownership is expected to be completed in the first half of 2024.
“This acquisition aligns perfectly with our business objectives and strengthens our commitment to Ireland,” said an MSD spokesperson. “The Dundalk facility’s expertise in live virus vaccines complements our existing network and positions us to better serve patients worldwide.”
Live virus vaccines, which use a weakened form of the germ to trigger a long-lasting immune response, are crucial in protecting against diseases like measles, mumps, rubella, and smallpox.
The acquisition comes as MSD, like many other U.S. multinationals, navigates a changing global landscape. With President-elect Donald Trump’s focus on prioritizing domestic investment, the move to expand operations in ireland underscores the country’s attractiveness as a hub for pharmaceutical manufacturing.
“MSD’s continued expansion in Ireland is a testament to the unique ecosystem we’ve cultivated,” said Samantha Humphreys, managing director of MSD Ireland Human Health. “Our talented workforce and supportive habitat have enabled us to achieve remarkable things, and we’re excited to build on this success.”
The Dundalk plant will become MSD’s eighth site in Ireland, adding to its existing network of five manufacturing facilities and three other locations. The company currently employs over 3,000 people in Ireland and expects to create an additional 1,000 jobs in the coming year.
Irish officials welcomed the news, highlighting the notable economic benefits and job creation opportunities.”This is a tremendous vote of confidence in Dundalk and County Louth,” said Taoiseach Simon Harris. “MSD’s investment will create high-quality jobs and contribute to the continued growth of Ireland’s pharmaceutical sector.”
Michael Lohan, CEO of IDA Ireland, echoed the sentiment, emphasizing MSD’s long-standing commitment to Ireland. “MSD has been a valued partner for nearly 50 years, and we’re delighted to see them deepen their roots in the country,” he said.
The acquisition marks a significant milestone for MSD and reinforces Ireland’s position as a global leader in pharmaceutical manufacturing.
Inside MSD’s €500 Million Vaccine Investment in Ireland
Sarah: Did you hear about MSD’s big news? They’re spending a whopping €500 million on a new vaccine plant in Dundalk!
David: Wow,that’s huge! I know MSD already has a presence in Ireland,but what’s driving this massive investment?
Sarah: Apparently,they’re buying a state-of-the-art facility from Wuxi Biologics. This plant has been making vaccines exclusively for MSD under a long-term contract, and now MSD is taking full ownership.
David: That makes sense. It must be strategic to have direct control over their vaccine production, especially with all the global health concerns lately.
Sarah: Absolutely.
They mentioned live virus vaccines in the press release – those are crucial for diseases like measles, mumps, and rubella. having their own dedicated site for these vaccines is a big deal.
David: I’m curious, what does this mean for Dundalk and the local economy?
Sarah: It’s great news! Not only are they keeping the existing 150 jobs, but they’re also planning to create even more.
David: That’s fantastic! Are there any quotes from MSD about their reasoning behind this expansion?
Sarah: Yes, a spokesperson said the acquisition aligns perfectly with their business objectives and strengthens their commitment to Ireland. The dundalk facility’s expertise in live virus vaccines complements their existing network and helps them serve patients worldwide.
David: Sounds like a win-win for everyone involved – MSD gets to expand, Ireland gets a boost to its economy, and patients get access to vital vaccines. What’s next for MSD in Ireland?
Sarah: Well, they’re already a major employer in Ireland with over 3,000 people working across their various sites. This plan adds another site, making it their eighth in the country, and they expect to create another 1,000 jobs in the coming year.
David: Wow, they seem very committed to Ireland. I’m sure this investment will be closely watched by other multinational companies looking for a stable and skilled workforce.
Sarah:** Definitely. Ireland has realy positioned itself as a hub for pharmaceutical manufacturing, and MSD’s continued expansion is a testament to that.